Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Acute, untreated, hepatitis C infection, genotype 1 or 4, with an estimated duration less than 24 weeks~* Confirmed HIV-1 infection~* CD4 T cell count \>200/μL for individuals receiving antiretroviral therapy (ART), CD4 T cell count \> 500/μL at screening for individuals without ART~* Use of two effective contraception methods if female of childbearing potential or sexually active male with female partner~Key Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Chronic liver disease of a non HCV etiology~* Coinfection with hepatitis B virus (HBV)~* Treatment with any investigational drug or device within 60 days of the screening visit.~* History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol~Note: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF (Type: EXPERIMENTAL): LDV/SOF FDC for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).